Back to search results

ICU Medical Costa Rica

Explore carbon emissions data for ICU Medical Costa Rica. Mycelium helps you review reported emissions, disclosure status, Scope 1, Scope 2 and Scope 3 data, climate targets and sustainability information in one company profile.

This profile brings together available carbon emissions data for ICU Medical Costa Rica, including reported figures, modelled estimates, disclosure documents and sustainability indicators, so you can review its emissions and compare its performance against similar companies. It is one entry in the Mycelium emissions database. Read how we source and check this data.

Emissions

Carbon emissions

Total yearly emissions across all scopes

377,806tCO2e(Location Based)(Mycelium adjusted)

Reported by ICU Medical Costa Rica
6,987 tCO₂e
Estimated by Mycelium
370,819 tCO₂e

ICU Medical Costa Rica reported 2% of the adjusted total. Mycelium estimated the remaining 98% for the categories it did not disclose.

Scope 1

tCO2e

3,193

Scope 2 (Location Based)

tCO2e

3,263

Scope 3 total

tCO2e

371,350

Figures from page 25 of the source report

Scope 3 reported

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

Something wrong? Contribute to this dataset

See the scope breakdown

Provenance

Review the sources and documents behind ICU Medical Costa Rica's emissions data. Provenance matters because it shows where the information comes from, how recent it is and how complete the disclosure appears to be.

Documents

Emissions
Factors

Modelled emission factorScope 1, 2 and upstream Scope 3 (categories 1–8)
0.130kgCO2e / $

Sustainability
Snapshot

Based on reported data, retrieved with AI

  • ICU Medical Costa Rica reported 6,987 tCO₂e in 2024.
  • Scope 3 accounted for 8% of reported emissions.
  • Reported across 1 of 15 GHG Protocol Scope 3 categories.
  • Scope 2 reported under the location based methodology.

According to available emissions disclosures, ICU Medical Costa Rica reported total yearly emissions of 6,987 tCO₂e in 2024. Scope 2 emissions accounted for 47% of the reported footprint, indicating purchased energy was the most significant contributor to its carbon footprint.

The company achieved a Mycelium Score of 0.1, placing it well below average for its sector for sustainability performance, and received a transparency score of 2.1, pointing to very little public detail on their key emissions.

Scope
breakdown

Scope 1 emissions

Direct emissions from sources the company owns or controls, such as fuel use, facilities and vehicles.

REPORTED

Direct emissions

3,193

tCO2e

Scope 2 emissions

Indirect emissions from purchased energy, including electricity, heating and cooling.

REPORTED

Location based

3,263

tCO2e

Market based

–

tCO2e

Scope 3 emissions

Wider value chain emissions across the 15 GHG Protocol categories, from purchased goods and business travel to investments, where reported.

ESTIMATED

Cat 1

Purchased goods & services

227,751

tCO2e
ESTIMATED

Cat 2

Capital goods

23,980

tCO2e
ESTIMATED

Cat 3

Fuel & energy related activities

6,190

tCO2e
ESTIMATED

Cat 4

Upstream transportation & distribution

37,035

tCO2e
REPORTED

Cat 5

Waste generated in operations

531

tCO2e
ESTIMATED

Cat 6

Business travel

2,741

tCO2e
ESTIMATED

Cat 7

Employee commuting

3,192

tCO2e
ESTIMATED

Cat 8

Upstream leased assets

860

tCO2e
ESTIMATED

Cat 9

Downstream transportation & distribution

10,237

tCO2e
ESTIMATED

Cat 10

Processing of sold products

7,926

tCO2e
ESTIMATED

Cat 11

Use of sold products

30,777

tCO2e
ESTIMATED

Cat 12

End-of-life treatment of sold products

10,427

tCO2e
ESTIMATED

Cat 13

Downstream leased assets

690

tCO2e
ESTIMATED

Cat 14

Franchises

8,061

tCO2e
ESTIMATED

Cat 15

Investments

950

tCO2e

14 values were derived via Mycelium's normalisation process rather than reported by the company. A cell marked “ESTIMATED” is a figure the company did not disclose, modelled by Mycelium.

Verification

Independent third parties involved in checking or preparing ICU Medical Costa Rica's emissions data.

Independent assurance

Independently assured(limited assurance)by Undergone, No name providedfor 2024

Contact Info

Website

icumed.com

Country

United States of America

Browse carbon emissions data by industry

How scoring works

How the Mycelium Score is calculated

The Mycelium Score is out of 10. Up to 6.5 points reflect carbon intensity vs peers in the same NACE section (emissions normalised against revenue, log-scaled between the 5th and 95th percentile of each company's latest reporting year in that section; a section needs at least 5 companies to be benchmarked). The band above 6.5 is earned through verified data quality on a claimed profile: declaring every reporting category yourself (up to 2.0), preparation by a carbon accountant (2.0) and independently audited figures (2.0). The total is multiplied by the transparency score and capped at 10. A disclosure with an implausibly large figure (Scope 1 or 2 over 300 million tonnes, a Scope 3 figure over 2 billion tonnes or a total over 2.5 billion tonnes) is not scored until it has been checked.

A higher score means lower carbon intensity than sector peers, backed by data that's third-party verified, claimed by the company, and fully disclosed. ICU Medical Costa Rica's score sits at the top of this page and in the score panel. Without a revenue figure to measure carbon intensity, or an industry classification to compare it within, a company has no score.

How the Transparency Score is calculated

The Transparency Score is the share of a company's estimated footprint that it reported itself, graded from A (very high) down to F (very low). Where a category is missing, Mycelium models what it would hold for a company of that size and industry and counts it as undisclosed, so an unreported category where the bulk of emissions sit hurts far more than a minor one. Unreported downstream categories (9 to 15) count at a quarter of their modelled size in this share; the carbon intensity behind the score still counts them in full. A Scope 3 total filed without a category breakdown earns very little credit for the part left unattributed, because it does not show which categories are inside it: a company can count business travel, leave purchased goods out entirely, and the total looks the same. Without a revenue figure the footprint cannot be modelled, so the company has no Transparency Score.

For ICU Medical Costa Rica, the single biggest gap is Purchased goods & services (Scope 3 Category 1). Mycelium estimates it accounts for around 60% of the company's estimated footprint, yet it hasn't been disclosed. Leaving a bucket this large unreported is what's holding the transparency score down.

Other material categories ICU Medical Costa Rica hasn't disclosed:

  • Upstream transportation & distribution (Scope 3 Category 4), around 10% of the estimated footprint
  • Use of sold products (Scope 3 Category 11), around 8% of the estimated footprint
  • Capital goods (Scope 3 Category 2), around 6% of the estimated footprint

In total, roughly 98% of ICU Medical Costa Rica's estimated emissions sit in categories it hasn't reported. Disclosing these would be the fastest way to raise the transparency score.

Cover of Mycelium's scoring methodology white paperRead the full scoring methodologyOur white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.Download the white paper (PDF)

Compare ICU Medical Costa Rica with similar companies

ICU Medical Costa Rica carbon emissions FAQs

What are ICU Medical Costa Rica's carbon emissions?

In its 2024 reporting year, ICU Medical Costa Rica disclosed total emissions of 6,987 tCO2e across all scopes. Including Mycelium estimates for undisclosed categories, the adjusted total is 377,806 tCO2e. Scope 2 accounted for the largest share of the reported total, around 47%.

Does ICU Medical Costa Rica report Scope 1, Scope 2 and Scope 3 emissions?

For 2024, ICU Medical Costa Rica's available disclosure covers Scope 1 (3,193 tCO2e), Scope 2 (3,263 tCO2e) and Scope 3 across 1 of the 15 GHG Protocol categories. Figures not reported by the company are shown as modelled estimates and labelled as such.

How transparent is ICU Medical Costa Rica's emissions reporting?

ICU Medical Costa Rica has a Mycelium transparency score of 2.1 out of 100. The score is the share of the company's estimated footprint that it reported itself, so an undisclosed category where most of its emissions sit weighs far more than a minor one.

Is ICU Medical Costa Rica sustainable?

Mycelium measures sustainability through carbon emissions data rather than giving a yes or no verdict. ICU Medical Costa Rica has a Mycelium Score of 0.1 out of 10, which reflects its emissions intensity against sector peers together with how transparent and well-verified its reporting is. The emissions figures and disclosure documents on this page give the fuller picture.

Is ICU Medical Costa Rica environmentally friendly?

Carbon emissions are one measurable part of environmental impact, and the part Mycelium tracks. ICU Medical Costa Rica disclosed 6,987 tCO2e for 2024, and its Mycelium Score of 0.1 out of 10 shows how that performance compares with similar companies in its sector.

Learn more about our methodology and where this data comes from.